[HTML][HTML] Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial
DC Smith, MR Smith, C Sweeney, AA Elfiky… - Journal of clinical …, 2013 - ncbi.nlm.nih.gov
DC Smith, MR Smith, C Sweeney, AA Elfiky, C Logothetis, PG Corn, NJ Vogelzang, EJ Small…
Journal of clinical oncology, 2013•ncbi.nlm.nih.govPurpose Cabozantinib (XL184) is an orally bioavailable tyrosine kinase inhibitor with activity
against MET and vascular endothelial growth factor receptor 2. We evaluated the activity of
cabozantinib in patients with castration-resistant prostate cancer (CRPC) in a phase II
randomized discontinuation trial with an expansion cohort.
against MET and vascular endothelial growth factor receptor 2. We evaluated the activity of
cabozantinib in patients with castration-resistant prostate cancer (CRPC) in a phase II
randomized discontinuation trial with an expansion cohort.
Abstract
Purpose
Cabozantinib (XL184) is an orally bioavailable tyrosine kinase inhibitor with activity against MET and vascular endothelial growth factor receptor 2. We evaluated the activity of cabozantinib in patients with castration-resistant prostate cancer (CRPC) in a phase II randomized discontinuation trial with an expansion cohort.
ncbi.nlm.nih.gov